1112 related articles for article (PubMed ID: 19637418)
21. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Hanauer SB; Panes J; Colombel JF; Bloomfield R; Schreiber S; Sandborn WJ
Aliment Pharmacol Ther; 2010 Aug; 32(3):384-93. PubMed ID: 20491747
[TBL] [Abstract][Full Text] [Related]
22. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
23. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
24. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
Schreiber S
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
[TBL] [Abstract][Full Text] [Related]
25. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
[TBL] [Abstract][Full Text] [Related]
26. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
Schreiber S; Lawrance IC; Thomsen OØ; Hanauer SB; Bloomfield R; Sandborn WJ
Aliment Pharmacol Ther; 2011 Jan; 33(2):185-93. PubMed ID: 21083671
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
28. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
Baker DE
Rev Gastroenterol Disord; 2008; 8(4):240-53. PubMed ID: 19107098
[TBL] [Abstract][Full Text] [Related]
29. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.
Augustine JM; Lee JK; Armstrong EP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):599-609. PubMed ID: 25209304
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
31. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
32. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
33. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
Leung Y; Hanauer SB
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
[TBL] [Abstract][Full Text] [Related]
34. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
35. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ; Abreu MT; D'Haens G; Colombel JF; Vermeire S; Mitchev K; Jamoul C; Fedorak RN; Spehlmann ME; Wolf DC; Lee S; Rutgeerts P
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):688-695.e2. PubMed ID: 20451663
[TBL] [Abstract][Full Text] [Related]
36. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
37. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
39. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
40. Certolizumab (Cimzia) for Crohn's disease.
Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]